Study Group: Oncology Physicians who Treat CID (US)(?)
Council Members in this Study Group: 24
Request a survey with this Study Group
Leading Experts in this Study Group
Donald Fleming, MD
Division Head of Hematology and Oncology
Davis Health System, Inc.
Donald Fleming, MD, is the Head of Hematology-Oncology at the Medical Center of Vincennes. Previously, Dr. Fleming was a Tenured Professor in the Division of Hematology-Oncology at University of Louisville. He has published over 25 manuscripts in peer-reviewed journals and remains involved in clinical...
Consultant
Medical Consulting Firm of Dr. Ben Ebrahimi
Ben Ebrahimi, MD, is Director of Clinical Trials at Wilshire Oncology Medical Group. Dr. Ebrahimi oversees clinical trials in various tumor types and treats a variety of cancer patients including lung, breast, colorectal, and lymphomas. These clinical trials include biological agents as well as targeted...
Taral Patel, MDOncologist
Mid Ohio Oncology Hematology Inc.
Taral Patel, MD, is an Oncologist in private practice with Mid Ohio Oncology-Hematology, Inc. He treats patients with both cancer and blood disorders. Dr. Patel has been a principal investigator for multiple clinical trials in colon cancer, lung cancer, lymphoma, and growth factor. He has been on the...
Professor of Clinical Medicine
Columbia University College of Physicians and Surgeons
Michael Grossbard, MD, is a Professor of Clinical Medicine at Columbia University College of Physicians and Surgeons and the Chief of Hematology-Oncology at St. Luke's-Roosevelt Hospital and Beth Israel Medical Center in New York City. His clinical research is in monoclonal antibodies, non-Hodgkin's...
Radiation Oncologist
St. Vincent's Comprehensive Cancer Center
Lawrence Tena, MD, is an Attending Physician in the Department of Radiation Oncology at St. Vincent's Comprehensive Cancer Center in New York. He is also an Assistant Professor of Radiation Oncology at the New York Medical College and an Associate Adjunct at the New York Eye and Ear Infirmary. Dr. Tena...
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
Novartis is looking for approval for therapy in C-KIT + Gastrointestinal stromal tumors
Bcl-2 inhibition by small molecules stands to be the next avenue for antineoplastic therapy- Looks like the real deal!
The FDA required Amgen to revise the label for Procrit and Aranesp so that these agents are not used until a patient's hemoglobin drops below 10 or in the setting of potentially curative therapy.
The author argues that transparency in healthcare will be an important step forward for the consumer.
Avastin improves survival in colon cancer and lung cancer and improves progression free survival in breast cancer- clinically meaningful outcomes. Yet these gains are of relatively short duration and the cost of Avastin is significant- 50,000 to 100,000 dollars per year.
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
- Consultancy, Healthcare-Focused
- Government/Military Hospital or Clinic
- Other Freestanding Healthcare Facility
Most Common Job Types:
- Physician - Attending Physician
- Physician - Director
- Physician - Division Head
- Partner
- Consultant
- Research Scientist
- Chief Executive Officer
- Owner
- President
- Director
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms